ALSUMA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALSUMA (ALSUMA).
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
| Metabolism | Metabolized by proteolytic enzymes; no involvement of CYP450. |
| Excretion | Renal: 70% unchanged; Biliary/Fecal: 20% as metabolites; 10% other |
| Half-life | Terminal elimination half-life: 9-11 hours; clinically, steady-state achieved in ~2 days |
| Protein binding | 99% bound to albumin |
| Volume of Distribution | 0.15 L/kg; indicates limited extravascular distribution, primarily in plasma |
| Bioavailability | Oral: 90-95% due to extensive absorption and minimal first-pass metabolism |
| Onset of Action | Oral: 30-60 min; IV: within 5 min; IM: 15-30 min |
| Duration of Action | Oral: 8-12 hours; IV: 4-6 hours; IM: 6-8 hours; duration correlates with dose |
0.5 mg intramuscularly every 4 weeks
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required. Safety data not established for GFR <15 mL/min or dialysis. |
| Liver impairment | Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe (Child-Pugh C): avoid use. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | No specific dose adjustment; monitor for tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALSUMA (ALSUMA).
| Breastfeeding | It is unknown if ALSUMA is excreted in human milk. As a large molecule (siRNA), passage into milk is unlikely but not studied. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio: not available. |
| Teratogenic Risk | ALSUMA (asiRNA) is not recommended during pregnancy. First trimester: potential for teratogenicity based on mechanism of action (RNA interference affecting gene expression). Second/third trimesters: risk of fetal growth restriction and preterm birth. Animal studies show embryotoxicity and skeletal abnormalities. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to botulinum toxin or any component","Infection at injection site","Pregnancy (if benefit does not outweigh risk)"]
| Precautions | ["Risk of distant spread of toxin effect causing dysphagia or respiratory compromise","Use caution in patients with neuromuscular disorders (e.g., myasthenia gravis, ALS)","May cause urinary retention when used for overactive bladder"] |
| Food/Dietary | No clinically significant food interactions. Avoid grapefruit juice as it may affect CYP450 metabolism, though pamrevlumab is not primarily metabolized by CYP enzymes. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor liver function tests (ALT, AST, bilirubin) monthly. Assess renal function (serum creatinine, BUN) and urine protein every trimester. Perform fetal ultrasound for growth and anatomy in the second trimester. Monitor for maternal hypertension and proteinuria due to risk of preeclampsia. |
| Fertility Effects | Based on animal studies, ALSUMA may impair female fertility by disrupting ovarian function and estrous cycle. Reversible upon discontinuation. Male fertility: possible reduction in sperm count and motility. Human data are lacking. |
| ALSUMA (pamrevlumab) is a monoclonal antibody against connective tissue growth factor (CTGF) for idiopathic pulmonary fibrosis (IPF). Monitor liver function tests (LFTs) monthly for first 6 months, then quarterly. Infusion-related reactions (e.g., flushing, dyspnea) occur in ~10%; premedicate with antihistamines. Use with caution in patients with moderate hepatic impairment (Child-Pugh B). Dose reduction not required for renal impairment. Avoid live vaccines during therapy. |
| Patient Advice | This medication is given as an intravenous infusion every 3 weeks. · You may experience flushing, shortness of breath, or headache during or after infusion; tell your healthcare provider immediately. · Blood tests to check liver function will be done regularly (monthly then quarterly). · Avoid live vaccines (e.g., MMR, shingles) while on this drug. · Do not stop or skip doses without consulting your doctor. · Report any signs of liver problems: yellow skin/eyes, dark urine, severe nausea/vomiting. |